Skip to main content
Premium Trial:

Request an Annual Quote

NIA to Spend $23M on Studies Seeking Alzheimer's Targets

NEW YORK (GenomeWeb News) – The National Institute on Aging plans to award up to $23 million in 2013 to fund efforts using systems biology, 'omics, and other interdisciplinary approaches to identify and validate novel therapeutic targets in molecular networks that are involved in Alzheimer's disease.

Developed as a response to recommendations from the Alzheimer's Disease Research Summit, which was created under the National Alzheimer's Project Act of 2011, this grant program seeks to spur efforts that will lead to new pharmacological targets for treating AD.

These projects will use systems biology and systems pharmacology approaches to understand how therapeutic targets operate within molecular and physiological systems and to identify and validate such targets. The research is expected to demonstrate how particular targets are involved in disease and to show the "druggability" of these targets — whether they can be modulated with small molecule or chemical probes or biologics, NIA said in its request for applications late last week.

These studies should aim to gain a systems-level understanding of the gene, protein, and metabolic networks that these targets operate within. NIA also is encouraging researchers to identify pharmacodynamic response biomarkers as part of the early validation process.

The tools and technologies researchers will use in these projects will include conditional knock-out/knock in transgenics, siRNA screens, chemical biology screens, among others.

The researchers also will be expected to integrate clinical samples and clinical data, including genomic, epigenomic, proteomic, metabolomic, expression profiling, and imaging data.

NIA said it is particularly interested in supporting studies focused on the discovery and preclinical validation of novel targets associated with molecular processes that lead to declines in cognitive function, mechanisms involved in metabolic and vascular factors, and other mechanisms that elevate AD risk and neuropsychiatric symptoms in AD.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.